Type 2 diabetes.
Metformin, first-line biguanide therapy, reduces hepatic gluconeogenesis.
Glimiperide, a sulfonylurea, increases insulin secretion from pancreatic beta cells.
Sitagliptin and vildagliptin, DPP-4 inhibitors, prolong incretin action.
Dapagliflozin and empagliflozin, SGLT2 inhibitors, promote glycosuria.
Pioglitazone, a thiazolidinedione, improves insulin sensitivity.
Semaglutide and liraglutide, injectable GLP-1 receptor agonists for glycemic control.
Insulin aspart, glargine, rapid-acting and long-acting insulin analogs.

Depression.
Escitalopram and sertraline, selective serotonin reuptake inhibitors, first-line for major depressive disorder.
Venlafaxine and duloxetine, serotonin nor-epinephrine reuptake inhibitors.
Amitriptyline, imipramine, tricyclic antidepressants used for neuropathic pain as well.
Mirtazapine, atypical antidepressant useful in depression with insomnia.
Olanzapine, atypical antipsychotic often used as adjunct in treatment resistant depression.